Arax Advisory Partners’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
Other funds holding AKBA
Arax Advisory Partners's AKBA Position: Q3 2026 in Review
Arax Advisory Partners reduced its Akebia Therapeutics (AKBA) stake by 10% in Q3 2026, selling an estimated $5.89K and leaving 49,522 shares worth $45.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3400.
Arax Advisory Partners first reported a position in AKBA in Q4 2024 and has held it in 8 quarters since. The position peaked at $108K in Q3 2025. 120 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.
- Arax Advisory Partners held 49,522 shares of Akebia Therapeutics worth $45.6K as of Q3 2026.
- Arax Advisory Partners sold 5,477 Akebia Therapeutics shares in Q3 2026, an estimated $5.89K.
- Akebia Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #3400 holding.
- Arax Advisory Partners first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 8 quarters since.
- Arax Advisory Partners's Akebia Therapeutics position peaked at $108K in Q3 2025.
- 120 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.
Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.